Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer

被引：0
|
作者：
Courtier, Baudouin [1 ]
Pierret, Thomas [2 ]
机构：
[1] Hop St Louis, Serv Oncol Med, 1 Ave Claude Vellefaux, F-75010 Paris, France
[2] CHU Grenoble Alpes, Oncol Thorac, 1 Blvd Chantourne, F-38700 La Tronche, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 06期
关键词：
Lung cancer; Targeted therapies; RET; Metastases;
D O I：
10.1016/j.bulcan.2021.04.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：562 / 563
页数：2
相关论文
共 50 条
  • [21] Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports
    Huang, Nai-Si
    Chen, Jia-Ying
    Meng, Yan
    Li, Qiu-Li
    Ji, Qing-Hai
    Wang, Yu
    [J]. ORAL ONCOLOGY, 2024, 159
  • [22] Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer
    Curigliano, G.
    Subbiah, V.
    Gainor, J. F.
    Lee, D. H.
    Taylor, M. H.
    Zhu, V.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 790 - 790
  • [23] Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Drilon, A.
    Subbiah, V.
    Gautschi, O.
    Tomasini, P.
    De Braud, F. G. M.
    Solomon, B.
    Tan, D. Shao-Weng
    Alonso, G.
    Wolf, J.
    Park, K.
    Goto, K.
    Soldatenkova, V.
    Szymczak, S.
    Barker, S.
    Puri, T.
    Lin, A. B.
    Loong, H. H. F.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S43 - S43
  • [24] Selpercatinib (LOXO-292) in patients with RET-fusion plus non-small cell lung cancer.
    Goto, Koichi
    Oxnard, Geoffrey R.
    Tan, Daniel Shao-Weng
    Loong, Herbert H. F.
    Bauer, Todd Michael
    Gainor, Justin F.
    McCoach, Caroline Elizabeth
    Gautschi, Oliver
    Besse, Benjamin
    Cho, Byoung Chul
    Peled, Nir
    Weiss, Jared
    Kim, YuJung
    Ohe, Yuichiro
    Horiike, Atsushi
    Park, Keunchil
    Huang, Xin
    Olek, Elizabeth
    Subbiah, Vivek
    Drilon, Alexander E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
    Drilon, A.
    Oxnard, G. R.
    Tan, D. S. W.
    Loong, H. H. F.
    Johnson, M.
    Gainor, J.
    McCoach, C. E.
    Gautschi, O.
    Besse, B.
    Cho, B. C.
    Peled, N.
    Weiss, J.
    Kim, Y. -J.
    Ohe, Y.
    Nishio, M.
    Park, K.
    Patel, J.
    Seto, T.
    Sakamoto, T.
    Rosen, E.
    Shah, M. H.
    Barlesi, F.
    Cassier, P. A.
    Bazhenova, L.
    De Braud, F.
    Garralda, E.
    Velcheti, V.
    Satouchi, M.
    Ohashi, K.
    Pennell, N. A.
    Reckamp, K. L.
    Dy, G. K.
    Wolf, J.
    Solomon, B.
    Falchook, G.
    Ebata, K.
    Nguyen, M.
    Nair, B.
    Zhu, E. Y.
    Yang, L.
    Huang, X.
    Olek, E.
    Rothenberg, S. M.
    Goto, K.
    Subbiah, V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 813 - 824
  • [26] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
    Griesinger, Frank
    Curigliano, Giuseppe
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel S. W.
    Lee, Dae H.
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    van der Wekken, Anthonie J.
    Gainor, Justin F.
    Paz-Ares, Luis
    Liu, Stephen, V
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Mansfield, Aaron S.
    Lin, Jessica J.
    Smoljanovic, Vlatka
    Rahman, Ahmadur
    Zalutskaya, Alena
    Louie-Gao, Melinda
    Boral, Andy L.
    Mazieres, Julien
    [J]. FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306
  • [27] Targeting RET alterations in non-small cell lung cancer
    Nishikawa, Go
    Klein, Mark A.
    [J]. CURRENT PROBLEMS IN CANCER, 2024, 49
  • [28] Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
    Sherman, Eric Jeffrey
    Wirth, Lori J.
    Shah, Manisha H.
    Cabanillas, Maria E.
    Robinson, Bruce
    Laskin, Janessa J.
    Kroiss, Matthias
    Subbiah, Vivek
    Drilon, Alexander E.
    Wright, Jennifer
    Soldatenkova, Victoria
    French, Pearl Plernjit
    Italiano, Antoine
    Weiler, Daniela
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
    Jeon, Youngkyung
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Lee, Se-Hoon
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1144 - 1151
  • [30] Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study
    Liao, Dehua
    Long, Minghui
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Yan, Ting
    Yang, Desong
    [J]. LUNG CANCER, 2024, 196
12345